Biogen Ends Its Corporate Venture Efforts
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen CEO George Scangos spoke about the unnecessary overlap of the company's corporate venture fund and its business development unit at Windhover's recent Pharmaceutical Strategic Alliance conference.
You may also be interested in...
Biogen's New EVP Commercial Ops Tony Kingsley: An Interview With "The Pink Sheet" DAILY
Execution, discipline, and reliance on proven sales and marketing methods helped turn around key multiple sclerosis drug Avonex, says Biogen's new EVP, Global Commercial Operations.
Biogen's New EVP Commercial Ops Tony Kingsley: An Interview With "The Pink Sheet" DAILY
Execution, discipline, and reliance on proven sales and marketing methods helped turn around key multiple sclerosis drug Avonex, says Biogen's new EVP, Global Commercial Operations.
Pharma BD Heads Weigh The Benefits Of Corporate Venture Investing
Heads of business development from some of the world's largest pharmaceutical companies weigh in on the role business development plays in accessing tomorrow's innovations at the recent PSA conference.